Prescription Pharmaceutical News from “The Pink Sheet” DAILY

Pfizer’s Biosimilar Program: A MAB Dash After Biocon Deal Ends / Following the breakup in March of its insulin biosimilars deal with Biocon, Pfizer confirms plans to develop monoclonal antibody biosimilars on its own, and has put its first candidate, rituximab, into Phase 1 testing. / “The Pink Sheet”

OTCs and Nutritionals from “The Tan Sheet”

Perrigo Squares Off With Dr. Reddy’s In Lansoprazole Launch / FDA denied Perrigo’s petition that had sought to block Dr. Reddy’s ANDA for generic Prevacid 24HR because it used bioequivalence data for the proton pump inhibitor’s Rx version. / “The Tan Sheet”

Medical Device News from “The Gray Sheet”

Agilent Builds Cancer Diagnostics Biz Via Dako Acquisition For $2.2 Billion / Research and testing product maker Agilent gains Dako’s c-Kit pharmDx and HER2 FISH pharmDx assays, among other cancer diagnostics, in the firm’s largest acquisition to date. / “The Gray Sheet”

Top Medical News from Elsevier Global Medical News

Neoadjuvant Abiraterone Helps Clear Aggressive, Early-Stage Prostate Tumors / At 24 weeks, a pathological complete response or near pCR was achieved by 34% of men randomized to neoadjuvant abiraterone combination therapy, compared with 15% of men given leuprolide followed by an abiraterone regimen (P value = .089). / Elsevier Global Medical News